Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TTY Biopharm CoROCO:4105 +0.39%83 EBITDA Margin % is 41.51% as of Mar. 2026, which is 21% above its 10-year median of 34.36. GuruFocus rates ROCO:4105 with a GF Score™ of 83/100 and a GF Value™ of NT$87.56 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 959 Drug Manufacturers companies, TTY Biopharm Co ranks better than 91.87% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. TTY Biopharm Co's EBITDA for the
three
months ended in Mar. 2026 was NT$631 Mil. TTY Biopharm Co's Revenue for the
three
months ended in Mar. 2026 was NT$1,520 Mil. Therefore, TTY Biopharm Co's EBITDA margin for the quarter that ended in Mar. 2026 was 41.51%.
TTY Biopharm Co (ROCO:4105) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
TTY Biopharm Co EBITDA Margin % Related Terms
TTY Biopharm Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for TTY Biopharm Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4105 vs ZTS, UTHR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, TTY Biopharm Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TTY Biopharm Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TTY Biopharm Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where TTY Biopharm Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TTY Biopharm Co (ROCO:4105) has a EBITDA Margin % of 41.51% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on TTY Biopharm Co and its competitors. This is 21% above median its historical median of 34.36. Over the past decade, TTY Biopharm Co's EBITDA Margin % has ranged from 28.08 to 45.36. According to the industry distribution chart, TTY Biopharm Co ranks #78 out of 959 companies in the Drug Manufacturers industry, placing it in the top 8.1%.
Is TTY Biopharm Co's EBITDA Margin % too high?
TTY Biopharm Co's current EBITDA Margin % of 41.51% is 21% above median its 10-year median of 34.36. Over the past 10 years, this metric has ranged from a low of 28.08 to a high of 45.36. The Drug Manufacturers industry median EBITDA Margin % is 12.54. TTY Biopharm Co's value of 41.51% is 231% above this industry median. Based on the distribution chart, TTY Biopharm Co ranks #78 out of 959 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, TTY Biopharm Co has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TTY Biopharm Co's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, TTY Biopharm Co ranks #78 out of 959 companies for EBITDA Margin %. This places TTY Biopharm Co in the top 8% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.54. TTY Biopharm Co's value of 41.51% is 231% above this benchmark. Historically, TTY Biopharm Co's own EBITDA Margin % has ranged from 28.08 to 45.36 over the past decade. While the company's 10-year median is 34.36 vs. the industry median of 12.54, TTY Biopharm Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.54, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TTY Biopharm Co's current EBITDA Margin % of 41.51% is 231% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on TTY Biopharm Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TTY Biopharm Co's current EBITDA Margin % is 41.51%, which is 21% above median its own 10-year median of 34.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TTY Biopharm Co stock overvalued right now?
Based on GuruFocus' analysis, TTY Biopharm Co (ROCO:4105) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$87.56, compared to a current price of NT$78.10 — trading 10.8% below its estimated fair value. The current EBITDA Margin % is 41.51%, which is 21% above median its 10-year median of 34.36 and 231% above the Drug Manufacturers industry median of 12.54. TTY Biopharm Co's overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For TTY Biopharm Co (ROCO:4105), the current EBITDA Margin % is 41.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TTY Biopharm Co (ROCO:4105) Overvalued in 2026?
Based on GuruFocus' analysis, TTY Biopharm Co stock appears to be undervalued.
The current stock price of NT$78.10 is trading 10.8% below its estimated GF Value™ of NT$87.56.
GuruFocus considers TTY Biopharm Co to be Modestly Undervalued.
Key valuation signals for ROCO:4105:
EBITDA Margin %: 41.51% (21% above median its 10-year median of 34.36)
GF Value™: NT$87.56 vs. price of NT$78.10 (10.8% below fair value)
Industry Position: 231% above the Drug Manufacturers median (#78 of 959)
No single metric tells the full story. See the ROCO:4105 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TTY Biopharm Co Ltd is engaged in the manufacturing and marketing of pharmaceuticals and chemical drugs. The company's operating segments includes Oncology Business unit, Health Care Business unit, Intensive Care Business Unit, Healthcare Business Unit, Export and CDMO Business unit segment. It generates maximum revenue from the Oncology segment. Geographically, it derives a majority of revenue from Taiwan and also has a presence in America. Some of its products include Algitab, Alginos, Sulfin, Metacin, Cepiro, Brosym, Colimycin, Cubicin, and others.
83GF Score
Get the complete analysis for ROCO:4105
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4105 has been successfully added to your 
